Brazil Medical Device Registration: How Is Product Classification Determined?

How Is Product Classification Determined for Medical Device Registration in Brazil?

Answer: Companies should first confirm the target country, the risk classification of the product, the applicable regulatory pathway and the documentation already available, and then assess technical documentation, quality management system evidence, labelling and instructions for use, local representation, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, incomplete dossiers or undefined authorization arrangements do not extend the project timeline. For Chinese medical device manufacturers, the more reliable approach is to complete the product classification and documentation gap assessment first, and only then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Registration in Brazil typically affects technical documentation, the authorized representative, importer cooperation, labelling language, quality management system evidence and subsequent change control at the same time. If a project is driven only by the question of “which documents must be submitted,” deficiencies or rework are likely to arise in model coverage, evidence chain consistency, label claims and control over certificates. AIMEILI recommends that companies plan this question within a GHWP member-state and multi-country market access strategy, using one reusable core technical file to support localization in different markets, rather than rebuilding documentation from scratch for each country.

Published: 11 July 2026, 22:07 | Updated: 11 July 2026, 22:07

This article reviews the questions that companies must assess first in real projects concerning international medical device registration, documentation preparation, compliance pathways and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documentation and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI Viewpoint
• Frequently Asked Follow-up Questions
• Further Reading
• Scope of Application

Key Summary

On the question of how to determine medical device product classification for Brazil registration, companies should first confirm the target country, the product risk level, the applicable regulatory pathway and the existing documentation base, and then assess technical documentation, quality management system evidence, labelling and instructions for use, local representation, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission, to avoid extended project timelines caused by unclear classification, documentation or authorization arrangements. For Chinese medical device manufacturers, the more reliable approach is to complete the product classification and documentation gap assessment first, and only then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Registration in Brazil typically affects technical documentation, the authorized representative, importer cooperation, labelling language, quality management system evidence and subsequent change maintenance at the same time. If the project is driven only by the question of which documents must be submitted, deficiencies or rework are likely in model coverage, evidence chain consistency, label claims and control over certificates. AIMEILI recommends that companies plan this question within a GHWP member-state and multi-country market access strategy, using one reusable core technical file to support localization in different markets, rather than rebuilding documentation for each country on an ad hoc basis.

Applicable Scenarios and Core Questions

Companies searching for how to determine medical device product classification for Brazil registration are usually not looking for a conceptual explanation. What they need to resolve is whether their existing documentation can support a Brazilian submission, whether a local agent or authorized representative is required, why timelines become extended, and which issues could affect their launch plan. Behind this question there are usually several linked topics: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the process for a single country is not sufficient. A more valuable approach is to first develop reusable versions of the core technical file, quality management system evidence, performance verification, clinical evidence and labelling/instructions for use, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, conditions of use, method and duration of body contact, whether the device is sterile, whether it is powered, and whether it incorporates software or has IVD characteristics, and then determine the risk level and submission pathway. Once the pathway assessment is wrong, all subsequent translation, notarization, authorization, testing and supplementary documentation work will move in the wrong direction.

For a Brazilian project, it is also necessary to confirm the applicant entity and the boundaries of local responsibility: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely only in commercial contracts, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality management system evidence, technical file, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labelling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. Claims in the instructions for use, the models covered by test reports, the scope of applicability of clinical evidence, risk management conclusions, label warnings and information in the registration application form must support one another. Regulators focus on whether the device is safe, effective and traceable for its intended use, not on how many documents a company has uploaded.

Common Errors

The most common problem is that companies treat a registration project as a simple document submission, without first clarifying the product classification, evidence coverage and local responsibility relationships.

• Translating NMPA documentation directly and submitting it without restructuring the evidence according to the Brazilian pathway.
• Including too many models and specifications while test reports, clinical evidence or labelling coverage is insufficient.
• Selecting a local agent solely on the basis of sales cooperation, without defining regulatory responsibility, control over the certificate and post-market maintenance obligations.
• Inconsistency between labels, instructions for use, promotional materials and registration documentation claims, resulting in deficiency letters or post-market compliance risk.
• Failure to plan multi-country documentation reuse in advance, resulting in repeated preparation for each country and inflated cost and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission has begun.

• Compile the target product list, model and specification matrix and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English-language instructions for use.
• Confirm the responsibilities, costs, certificate control and exit mechanism of the local agent or authorized representative.
• Establish a target-country gap assessment table identifying what must be retested, translated, notarized or supported by additional declarations.

AIMEILI Viewpoint

AIMEILI recommends that companies do not view Brazil registration as a one-time document submission, but manage it as an overseas market access programme. For companies preparing to enter multiple countries, building a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster, more stable and more advantageous for later changes and certificate renewals than assembling documentation country by country at short notice.

From a project management perspective, three things should be controlled in advance: first, the product classification and pathway decision; second, the consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of the local partner. Unless these three items are clear, a project may still encounter repeated issues during deficiency responses, agent communication and post-market maintenance, even if the documentation appears extensive.

Frequently Asked Follow-up Questions

Can domestic documentation be used directly for Brazil registration?

Domestic documentation can serve as a foundation, but it usually cannot be submitted as is. Companies need to adjust the documentation structure, language, labelling, authorization documents and evidence chain in accordance with local regulatory requirements.

When is the best time to start a gap assessment?

It is advisable to start as soon as the target markets and product list are confirmed. The earlier the gap assessment is completed, the more time there is to arrange retesting, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent generally participates in registration communication, changes, certificate renewal and post-market event handling. Unclear responsibilities and rights will affect control over the certificate and the stability of the subsequent market position.

Project Execution Guidance

When executing this type of registration project, companies should maintain a project register that manages the product list, model and specification data, registration pathway, documentation owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This allows documentation gaps to be identified promptly and enables management to judge whether the project will affect the launch plan.

Companies that already have registrations in several countries should also build an evidence reuse matrix that defines which documents can serve as core evidence and which must be reissued or supported by additional statements in accordance with national requirements. In particular, labelling and instructions for use, clinical evaluation, risk management, performance verification and quality management system certificates must be kept at consistent versions.

• Confirm target markets and the product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and control over the certificate.
• Track translation, notarization, testing and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality Management System and Evidence Consistency

From a registration review perspective, quality management system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent. If the scope covered by the ISO 13485 certificate does not match the products being submitted, or if the manufacturing address, model and specification data, or the version of the instructions for use does not match the test reports, additional clarification may be requested even if a large number of documents has been prepared.

Before submission, companies should build an evidence consistency checklist that maps the product name, model and specification data, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and instructions for use version, and quality management system certificate item by item. This step may appear basic, but it can significantly reduce the probability of deficiency letters, particularly for projects involving simultaneous submissions in multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibilities

A Brazilian registration project generally involves arrangements with a local agent, authorized representative, importer or registration holder. Companies need to confirm in advance whether the local partner is responsible only for submitting documentation, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect control over the certificate and the stability of the subsequent market position.

Labelling, instructions for use and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable in the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Completion of registration does not mean the compliance work is finished. Companies also need to maintain certificate validity periods, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest considerable effort in obtaining the certificate but neglect post-market maintenance; when a manufacturing address change, model extension, instructions for use update or agent replacement occurs later, the certificate and actual market sales can easily become disconnected.

AIMEILI recommends that companies manage this question within an annual international registration plan: first define target market priorities, then build a reusable documentation package and a country-specific gap list, and finally schedule submission, deficiency response, post-market maintenance and certificate renewal milestones. The value of this approach is not only improved efficiency for a single country registration, but also the development of a replicable compliance capability for going global, reducing the cost of starting documentation from zero each time a new market is entered.

Further Reading

• Previous: How Should Registration Documentation for Brazil Medical Device Registration Be Prepared?
• Next: How Should the Technical File for Brazil Medical Device Registration Be Organized?
• Recommended: What Are the Risk Management Documentation Requirements for Medical Device Registration in the Philippines?
• Recommended: How Should Performance Verification Documentation for Medical Device Registration in the Philippines Be Prepared?
• Recommended: What Should Be Done When Quality Management System Evidence Is Inconsistent for Medical Device Registration in the Philippines?
• Recommended: How Should Registration Documentation for Medical Device Registration in Singapore Be Prepared?
• Recommended: How Is Product Classification Determined for Medical Device Registration in Singapore?
• Recommended: How Should the Technical File for Medical Device Registration in Singapore Be Organized?
• Back to the FAQ Centre
• News and Insights
• Contact AIMEILI

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team
Professional review: AIMEILI Medical Device International Registration Project Team
Source principles: Priority is given to official regulatory authorities, international organizations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting judgment.
Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.